New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…
U.K Minister for Culture Lisa Nandy presents $25,000 award to Dr. Shalini Mullick for her novel The Way Home LONDON,…
MANILA, Philippines, June 19, 2025 (GLOBE NEWSWIRE) -- Altius Inspiro, a leader in digital CX and outsourcing solutions, has proudly received…
Hyundai Motor Group premieres five commissioned artworks of the 6th VH AWARD screening at HEK (House of Electronic Arts) during…
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…
June 14, 2025 10:48 ET | Source: Celldex Therapeutics, Inc. 77% of patients (150 mg Q4W) treated with barzolvolimab who…
NEW DELHI, June 9, 2025 /PRNewswire/ -- The International Institute of Hotel Management (IIHM) has added another remarkable milestone to…
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…